Back OMCL confirms falsification of Ozempic® batches

EDQM Strasbourg, France 05/12/2023
  • Diminuer la taille du texte
  • Augmenter la taille du texte
  • Imprimer la page
  • Imprimer en PDF

Following concerns that falsified batches of Ozempic® may have entered the market, the Official Medicines Control Laboratory (OMCL) Chemisches und Veterinäruntersuchungsamt (CVUA, Karlsruhe, Germany) and a member of the European OMCL Network, has determined by analytical testing that suspected batches of Ozempic® pre-filled pens contained insulin glulisine instead of the claimed active substance, semaglutide. More information on this discovery can be found in a scientific paper published by CVUA on 22 November 2023 (in German).

Ozempic® is a medicinal product authorised to treat type 2 diabetes, but it has also become an extremely popular weight-loss treatment due to its appetite suppressant properties and ability to trigger insulin production. This off-label use for weight-loss has led to shortages in the legal supply chain, making it a prime target for falsification. Since October 2023, authorities from several countries have issued warnings concerning dangerous falsified versions of Ozempic® pens, which if used could have life-threatening consequences, including hypoglycaemic shock and coma.

See also:           

Image copyright: CVUA Karlsruhe